A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514246-37-00

Enrollment

Registered

2026-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic pulmonary fibrosis (IPF)

Brief summary

Week 24

Detailed description

1- Efficacy thorughout the duration of the study at Weeks 0, 6, 12, 18, 24 and 30, 2 - Week 0 through to Week 21

Interventions

DRUG0.9% sodium chloride aqueous solution for IV infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Week 24	—

Secondary

Measure	Time frame
1- Efficacy thorughout the duration of the study at Weeks 0, 6, 12, 18, 24 and 30, 2 - Week 0 through to Week 21	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 29, 2026